- Our Team
- For Patients
- New Patient
- Current Patient
- New Patient
- Treatments & Services
- Medical Professionals
Advancing Breast Cancer Care: How Immunotherapy and Targeted Treatments Are Changing the Future
Breast cancer treatment has evolved dramatically over the past decade, offering patients more personalized and effective options than ever before. While surgery, chemotherapy, radiation therapy, and hormone therapy remain important components of care, new advancements in immunotherapy, targeted therapies, and antibody-drug conjugates (ADCs) are transforming outcomes and providing hope for patients facing even the most challenging diagnoses. Recent research continues to move treatment toward a more precise, individualized approach based on the unique biology of each patient’s cancer.
Immunotherapy: Harnessing the Power of the Immune System
One of the most significant advances in breast cancer treatment is immunotherapy. Unlike traditional therapies that directly attack cancer cells, immunotherapy helps the body’s immune system recognize and destroy cancer more effectively.
Immunotherapy has shown particular promise in patients with triple-negative breast cancer (TNBC), an aggressive subtype that lacks estrogen, progesterone, and HER2 receptors. Immune checkpoint inhibitors, such as pembrolizumab, work by removing barriers that prevent the immune system from attacking cancer cells. For eligible patients, these therapies have improved outcomes and expanded treatment options where few previously existed.
“The progress we’ve seen in breast cancer treatment over the last several years has been remarkable. New therapies, including immunotherapy and antibody-drug conjugates, are expanding options for patients and helping us treat certain types of breast cancer with greater precision. These innovations are giving many patients renewed hope and improved quality of life.”
— Dr. Nadia Ashai, Medical Oncologist, Maryland Oncology Hematology
Researchers are now investigating how immunotherapy can be used in combination with other treatments to enhance effectiveness and extend benefits to a broader range of breast cancer patients.
Antibody-Drug Conjugates: Delivering Treatment with Precision
Another groundbreaking advancement is the development of antibody-drug conjugates (ADCs), a newer class of targeted therapies that combine the precision of an antibody with the cancer-fighting strength of chemotherapy.
These treatments work by identifying proteins found on cancer cells, delivering chemotherapy directly to the tumor while limiting damage to healthy tissue. ADCs such as trastuzumab deruxtecan and sacituzumab govitecan have significantly expanded treatment options for patients with HER2-positive, HER2-low, and triple-negative breast cancers. Experts now describe ADCs as revolutionizing breast cancer treatment and reshaping treatment strategies across multiple breast cancer subtypes.
Ongoing studies are exploring ADCs earlier in the course of treatment and in combination with immunotherapy, potentially offering even greater benefits to patients. Researchers believe this combination may create a powerful synergy by enhancing the immune system’s ability to recognize and attack cancer cells.
More Precise Targeted Therapies
Advances in genetic and molecular testing have also led to highly targeted treatments designed to attack specific cancer pathways. Physicians can now identify certain mutations or biomarkers within a tumor and select therapies that may be more effective for that individual patient.
For patients with hormone receptor-positive breast cancer, targeted medications continue to improve disease control while helping delay progression. At the same time, advances in HER2-directed therapy have dramatically changed the outlook for many patients with HER2-positive and HER2-low breast cancers. This personalized approach allows treatment decisions to be tailored to the specific biology of each patient’s disease.
The Role of Clinical Trials
Many of today’s most promising therapies became available through clinical trials, and ongoing research continues to drive innovation. Clinical trials provide eligible patients access to emerging therapies while helping researchers develop the next generation of breast cancer treatments.
Current studies are evaluating novel immunotherapy combinations, next-generation antibody-drug conjugates, and more personalized treatment approaches that may further improve outcomes while reducing treatment-related side effects.
Looking Ahead
The future of breast cancer treatment is increasingly personalized, precise, and hopeful. Innovations such as immunotherapy and antibody-drug conjugates are changing how breast cancer is treated, offering more effective options tailored to the biology of each patient’s disease. As research continues to advance, patients can expect greater access to therapies that not only improve survival but also enhance quality of life throughout their cancer journey.
At Maryland Oncology Hematology, patients have access to comprehensive breast cancer care and innovative clinical trials through Sarah Cannon Research Institute. By combining advanced treatment options with compassionate, multidisciplinary care, our team is committed to helping patients benefit from the latest breakthroughs in breast cancer research and treatment.